ARIAD to Webcast Presentation at the JPMorgan 9th SMid Cap Conference.

CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its presentation at the JPMorgan 9th SMid Cap Conference at the Four Seasons Hotel in Boston, Massachusetts on Monday, November 5, 2007 will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor.

The presentation will be given at 8:45 a.m. (EST) by Timothy P. Clackson, Ph.D., senior vice president and chief scientific officer of ARIAD, who will provide an overview of the Company and its progress in key programs. A replay will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for two weeks.

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate. Medinol Ltd. and ICON Medical Corp. are also developing deforolimus-eluting stents to prevent restenosis of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB treatment methods, and the discovery and development of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.